Impel Pharmaceuticals (FRA:84P) ROCE % : 0.00% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Impel Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Impel Pharmaceuticals's annualized ROCE % for the quarter that ended in Sep. 2023 was 0.00%.

Impel Pharmaceuticals ROCE % Historical Data

The historical data trend for Impel Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Impel Pharmaceuticals ROCE % Chart

Impel Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

ROCE %

-122.46

-234.30

-171.47

-116.16

Impel Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROCE %	Get a 7-Day Free Trial											-93.94	-92.62	-167.62	-	-

Impel Pharmaceuticals ROCE % Calculation

Impel Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-78.526	/	( ( (86.652 - 14.119)	+	(83.591 - 20.922) )	/ 2 )
	=	-78.526	/	( (72.533	+	62.669)	/ 2 )
	=	-78.526	/	67.601
	=	-116.16 %

Impel Pharmaceuticals's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	-48.016	/	( ( (41.357 - 111.887)	+	(32.863 - 116.884) )	/ 2 )
	=	-48.016	/	( ( -70.53	+	-84.021 )	/ 2 )
	=	-48.016	/	-77.2755
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

Impel Pharmaceuticals (FRA:84P) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Impel Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Impel Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Impel Pharmaceuticals (FRA:84P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Impel Pharmaceuticals Inc (FRA:84P) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

IMPLQ:USA

Address

201 Elliott Avenue West, Suite 260, Seattle, WA, USA, 98119

Website

https://www.impelpharma.com

Impel Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. The company is developing an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations.

Impel Pharmaceuticals (FRA:84P) Headlines

No Headlines